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AbSTRACT
background. Diabetic Distal Symmetric Polyneuropathy 
(DSPn), despite being the most common and a disa-
bling diabetic complication, remains difficult to treat. It 
has led to rekindle our interest in Epalrestat which has 
the potential to alter the natural history of the disease. 
The present study was designed to evaluate the efficacy 
of Epalrestat in DSPn and to correlate its therapeutic 
efficacy with baseline erythrocyte sorbitol levels.
Methods. One hundred patients with duration of dia-
betes more than five years and Diabetic Neuropathy 
Symptom Score (DnSS) ≥ 1 were included. They were 
divided into two groups of 50 patients each: group 1 
(received Epalrestat 150 mg Tablet once a day), group 
2 (received placebo). baseline Diabetic neuropathy 
Symptom Score (score out of 4), numeric Pain Inten-
sity Scale (NPIS; score out of 10), monofilament score 
(score out of 10), Vibration Perception Threshold (VPT) 
by Sensitometer and erythrocyte sorbitol levels (by 
ElISA) were recorded. Same parameters were repeated 
at three months follow up visit.
Results. The mean improvement in DnSS score was 2.39 
± 1.1 in group 1 vs 0.57 ± 1.04 in group 2; P < 0.01. 
Similarly there was a significant difference in improve-
ment in monofilament score in the two groups (2.82 
± 1.41 in group 1 vs 0.12 ± 0.93 in group 2; p< 0.01), 
in nPIS score (2.61 ± 1.26 in group 1 vs 0.41 ± 0.81 
in group 2; P < 0.01). Average VPT score improved by 
3.48 ± 2 in group 1 vs 0.34 ± 1.14 V in group 2; P < 
0.01). Improvement in VPT score with Epalrestat was 
correlated with baseline erythrocyte sorbitol levels 
(correlation coefficient of 0.911; P < 0.0001).
Conclusions. Epalrestat was overall more effective 
than placebo in improving the symptoms as well as 
in improving the quantitative sensory nerve function 
measured by sensitometer. The improvement in all the 
parameters positively correlated with baseline eryth-
rocyte sorbitol levels. Sorbitol levels can be a useful 
tool in predicting the response to drug. (Clin Diabetol 
2021; 10; 4: 354–358)
Key words: diabetic peripheral neuropathy, 
Epalrestat, sorbitol, vibration perception threshold.
Introduction
Diabetes Mellitus (DM) and its various complica-
tions have contributed enormously to the burden of 
morbidity and mortality worldwide. Diabetic periph-
eral neuropathy (DPN) is the most prevalent diabetic 
complication, having a lifetime occurrence rate of 50% 
and also seen in around 8% of newly detected diabetic 
patients [1]. DPN incurs a huge health burden on the 
society by increasing the risk of foot ulceration and 
consequent amputation with a significant lowering of 
quality of life [2]. But despite enormous health conse-
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quences, still there are not many therapeutic options 
available for treating DPN, quite unlike other diabetic 
microvascular complications.
A host of biochemical pathways affecting a multi-
tude of metabolic factors have been implicated in the 
pathogenesis of DPN. Among many, polyol pathway 
plays an important role in the pathogenesis of nerve fiber 
damage [3]. Aldose reductase (AR) enzyme plays a key 
role in nerve tissue damage through NADPH dependent 
production of sorbitol from glucose thereby altering the 
redox status and cellular osmolarity of the nerve tissue 
leading to cellular damage [4]. Epalrestat is one of the 
commercially available aldose reductase inhibitors (ARIs).
Various studies have been conducted to evaluate the 
efficacy and safety of ARIs in prevention and treatment 
of DSPN with contrasting results. The Aldose Reductase 
Inhibitor–Diabetes Complications Trial (ADCT) was a large 
3-year trial which showed promising results [5] but a 
subsequent meta-analysis showed no overall benefit. [6] 
Judging from the novel mechanism by which Epalrestat 
works, it is imperative to rekindle interest in this drug for 
treatment of DPN. It is possible that ARIs are effective 
in DSPN only when baseline erythrocyte sorbitol levels 
are raised and the drug decreases sorbitol levels during 
the course of the treatment. This study was designed 
to evaluate the efficacy of Epalrestat in Diabetic Sym-
metrical Peripheral Neuropathy (DSPN) and whether 
erythrocyte sorbitol levels can be used as predictor of 
response to Epalrestat in DSPN.
Material and methods
This study was conducted in the Department of 
Endocrinology and Metabolism, University Hospital, 
Institute of Medical Sciences, Banaras Hindu University, 
Varanasi, India.
Selection of subjects
Subjects with diabetes and peripheral neuropa-
thy were included in the study after obtaining their 
informed consent. All diabetic patients with duration 
of diabetes ≥ 5 years were screened for symptoms 
of peripheral neuropathy by Diabetic Neuropathy 
Symptom Score (DNSS) (Supplemental table 1) and 
simultaneously Vibration Perception Threshold (VPT) 
was checked by sensitometer (Dhansai Lab, Mumbai). 
DNSS score ≥ 1 and VPT > 25 volts (V) was taken as 
evidence of peripheral neuropathy. 
The study was an open-label and prospective ran-
domized controlled trial in 100 patients with diabetic 
peripheral neuropathy. The randomization was done 
through a computer generated random sequence. 
The enrolled patient population was divided into two 
groups of 50 patients each: Group 1 (received Epal-
restat 150 mg Tablet once a day for 12 weeks) and 
Group 2 (received placebo). Each participant was given 
verbal information and was asked to report if they 
experienced any side effects related to the use of the 
treatment. All the patients received standard diabetes 
care and glycemic management was optimized. Three 
patients (1 patient in group 1 and 2 patients in group 
2) were lost to follow up.
The study was reviewed and approved by the Eth-
ics and Drug Trials committee of the institute. The trial 
was registered with Clinical Trial Registry of India as 
CTRI/2018/01/011527.
Inclusion Criteria: Duration of diabetes more than 
5 years, Diabetic Neuropathy Symptom score  1(Sup-
plemental table 1) and VPT > 25 Volts
Exclusion Criteria: Duration of diabetes less than 
5 years, patients having active foot ulcer, subjects 
on drugs causing peripheral neuropathy or affecting 
sorbitol levels like Isoniazid, Amiodarone, Laxatives, 
anti-retroviral drugs etc., chronic alcohol consump-
tion, subjects with estimated glomerular filtration rate 
(eGFR) less than 60 ml/min, subjects with chronic liver 
disease, subjects with vitamin B12 deficiency.
Tools for comparison
All study subjects underwent assessment of various 
parameters at baseline and at 12 weeks. Neuropathy 
symptoms were assessed by Diabetic Neuropathic 
Symptom Score. Pain was recorded as 0–10 on numeric 
pain intensity scale. A neurological examination for 
neuropathy was done for each patient. Monofilament 
testing at five sites on each foot (big toe, 1st metatarsal 
head, 3rd metatarsal head, 5th metatarsal head, and 
heel) was done at baseline and at 12 weeks. 
Vibration perception threshold testing
VPT was tested using Sensitometer, Dhansai Labo-
ratory, Mumbai. After explaining the procedure prop-
erly to the subject, the probe was applied to greater 
toe, 1st metatarsal, 3rd metatarsal, 5th metatarsal and 
heel of both the feet with the patient in supine position 
in a quiet room. The vibration was increased gradually 
from minimum voltage and transition from no vibra-
tion to the onset of perceiving vibration was taken as 
the vibration perception threshold score. The Yes/No 
method was used. The VPT was tested on five areas on 
each foot. An average of all the values was taken as VPT 
of the subject. The VPT was measured in volts. A voltage 
more than 25 V was taken as presence of neuropathy.
Erythrocyte sorbitol measurement 
Erythrocyte sorbitol levels were measured by Human 
Sorbitol Dehydrogenase (SDH) Elisa kit (Sincere Biotech 
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Co., Beijing, China) as per the protocol provided by the 
manufacturer. Absorbance of each well was read at the 
wavelength of 450 nm in ELISA reader (BIOTEK, India).
Statistical analysis
Quantitative variables were compared using Inde-
pendent t test/Mann-Whitney Test (when the data sets 
were not normally distributed) between the two groups. 
Qualitative variables were correlated using Chi-Square 
test/Fisher’s exact test. Spearman rank correlation co-
efficient was used to assess the correlation of various 
parameters with erythrocyte sorbitol levels. A p value 
of <0.05 was considered statistically significant.
Results
baseline parameters
Both the study groups were comparable in terms 
of age and duration of diabetes. The study population 
in both the groups was evenly distributed across all age 
groups. Overall the duration of diabetes ranged from 
5 years to 26 years. The mean duration of neuropathy 
symptoms was 4 years in both the study groups. Both the 
study groups were comparable in terms of mean HbA1c 
and erythrocyte sorbitol levels at the baseline (Table 1).
Comparison of Epalrestat and placebo
The mean improvement in DNSS score was 2.39 
± 1.1 in group 1 vs 0.57 ± 1.04 in group 2; P < 0.01. 
Similarly there was a significant difference in improve-
ment in monofilament score and NPIS score in the two 
groups. Average VPT score improved by 3.48 ± 2 vs in 
group 1 vs 0.34 ± 1.14 V in group 2; P < 0.01) (Figure 1). 
Mean HbA1c was around 7.2% in both the groups at 
follow up visit (Table 2).
Table 1. baseline characteristics of the study groups
Parameter Epalrestat (group 1) n = 50 Placebo (group 2) n = 50 P value
Age (years) 50.4 ± 13.5 51.12 ± 12.84 0.785
Duration of diabetes (years) 10.08 ± 4.8 10.46 ± 5.08 0.890
DNSS score (out of 4) 4.78 ± 2.42 4.7 ± 2.24 0.006
Monofilament test (out of 10) 3.88 ± 2.43 3.64 ± 2.51 0.133
Numeric pain intensity scale (out of 10) 8.12 ± 1.19 8.04 ± 1.15 0.049
VPT (average) (in Volts) 32.05 ± 5.75 31 ± 6.36 0.275
HbA1c (%) 9 ± 1.61 8.99 ± 1.75 0.934
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Figure 1. Comparison of two study groups
Table 2. Follow up characteristics of the study groups
Parameter Epalrestat (group1) n = 49 Placebo (group2) n = 48 P value
DNSS score (out of 4)
Follow up visit 2.39 ± 1.1 0.57 ± 1.04 < 0.001
Monofilament test (out of 10)
Follow up visit 2.82 ± 1.41 0.12 ± 0.93 0.002
Numeric pain intensity scale (out of 10)
Follow up visit 2.61 ± 1.26 0.41 ± 0.81 < 0.001
VPT (average) (in Volts)
Follow up visit 28.7 ± 5.33 30.81 ± 6.67 0.116
HbA1c (%) Follow up visit 7.2 ± 1.18 7.17 ± 1.24 0.997
Erythrocyte sorbitol levels [ng/mL] Follow up visit 11.79 ± 3.09 14.59 ± 4.24 < 0.001
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Correlation of efficacy of Epalrestat  
with erythrocyte sorbitol levels
Reduction in sorbitol level with Epalrestat corre-
lated positively with baseline sorbitol levels (r = 0.867; 
p<0.0001) (Figure 2). Improvement in various param-
eters with Epalrestat was positively correlated with 
baseline erythrocyte sorbitol levels and improvement 
in VPT showed best correlation (r= 0.911; p<0.0001) 
with baseline erythrocyte sorbitol levels (Figure 3).
Discussion
Aldose reductase (AR), an aldo-keto reductase 
enzyme has been shown to be involved in the patho-
genesis of chronic microvascular diabetic complications 
[4]. ARIs have received a great deal of attention lately 
as an attractive therapeutic option for management 
of various long-term diabetic complications. There is 
a renewed interest in these drugs, of which only Epal-
restat is available in India [7]. The clinical efficacy of 
Epalrestat in DSPN is still not clear.
Our study showed that Epalrestat was overall more 
effective than placebo in improving the symptoms of DSPN 
as well as in improving the quantitative sensory nerve func-
tion measured by sensitometer. No major adverse events 
related to Epalrestat were noted in the study subjects. The 
higher the erythrocyte sorbitol levels at baseline, the greater 
was the decrease after Epalrestat treatment. Interestingly, 
improvement in various parameters with Epalrestat also 
correlated with baseline erythrocyte sorbitol levels. 
Figure 3. Showing correlation of improvement of (A) DNSS (B)  monofilament (C) VPT (D) NPIS with baseline erthyrocyte sorbitol 




















































Figure 2. Correlation between baseline erythrocyte sorbitol 
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ADCT which was a 3-year trial comprising 289 
and 305 patients respectively in the Epalrestat and 
placebo groups concluded that 150 mg daily Epalrestat 
appreciably prevented deterioration in median MNCV 
(median motor nerve conduction), MFWL (minimum 
F-wave latency) and VPT [5]. A Cochrane meta-analysis 
done in 2007 showed no statistically significant overall 
benefit of ARIs on neurological examination findings in 
diabetic polyneuropathy [6]. In an Indian study done by 
Sharma et al. in 2190 cases with diabetic neuropathy, it 
was shown that Epalrestat exerted an improvement in 
the subjective symptoms and nerve function tests. [8]. 
Ando et al. in a study concluded that decrease in eryth-
rocyte sorbitol levels during Epalrestat administration 
was significantly correlated with baseline erythrocyte 
sorbitol levels [9].
It may be possible that the drug works more ef-
fectively only in those patients who have excessive 
sorbitol accumulation at baseline. Additionally, the role 
of genetics in making an individual more susceptible 
to express inappropriately high sorbitol for the same 
degree of hyperglycemia cannot be refuted. Differences 
in enzyme activity and kinetics of AR in individuals may 
account for the differential response to ARIs [9].
Strengths of our study: It was a prospective study. 
Our study used both clinical as well as quantitative 
sensory parameters to evaluate the efficacy of Epal-
restat. Also the improvement in various parameters 
was correlated with baseline erythrocyte sorbitol levels.
Limitations of our study included limited duration 
of follow up period and failure to do nerve conduction 
studies (NCS) for evaluating the nerve function.
To conclude, our study shows that Epalrestat offers 
a ray of hope in ameliorating the symptoms of DSPN, 
which still remains one of the most difficult diabetic 
complications to treat. Erythrocyte sorbitol levels can 
be used to select the patients in which Epalrestat 
might work, thus paving the way for a personalized 
care strategy. 
Supplemental table 1. Diabetic neuropathy Symptom Score (Meijer et al.) [10]
Question asked Yes no Score
Are you suffering unsteadines while walking? 1 0 1 or 0
Do you have a burning, aching pain, or tenderness at your legs or feet? 1 0 1 or 0
Do you have prickling sensation at your legs and feet? 1 0 1 or 0
Do you have places of numbness on your legs of feet? 1 0 1 or 0
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